ReviewBiomedicines2022
Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced pancreatic cancer: a meta-analysis.World journal of surgical oncology · 2023Pooled it
- Global hotspots and trends of stereotactic radiotherapy for pancreatic cancer: a bibliometric analysis and visual analysis from 2015 to 2025.Translational cancer research · 2026Article
- Evaluation of the efficacy of plan adaptation in stereotactic body proton therapy for pancreatic cancer.Journal of applied clinical medical physics · 2026Article
- Pancreatic SBRT on four modern platforms: dosimetric and radiobiological gains with the Ethos ring-gantry linac versus TrueBeam, Halcyon, and helical tomotherapy.Radiation oncology (London, England) · 2026Article
- Review
- Developments & Potential of Nanotechnology for the Detection and Treatment of Pancreatic Cancer.International journal of nanomedicine · 2026Review
- CT imaging findings following treatment with combination SBRT and chemotherapy versus stand-alone chemotherapy for locally advanced pancreatic adenocarcinoma.Abdominal radiology (New York) · 2026Article
- Radiotherapy in the management of PDAC, from past to present.Translational oncology · 2026Review
- Machine-learning CT radiomics for prognostication in unresectable pancreatic cancer.Frontiers in pharmacology · 2026Article
- Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Usefulness and Limitations.Annals of surgical oncology · 2025Article
- Radiotherapy for Locally Advanced Pancreatic Cancer in the Modern Era: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Synergizing photodynamic therapy and ethanol ablation: Light-activatable sustained-exposure ethanol injection technology for enhanced tumor ablation.Bioengineering & translational medicine · 2025Article
- The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization.BMC gastroenterology · 2025Article
- Neoadjuvant Stereotactic Ablative Radiotherapy in Pancreatic Ductal Adenocarcinoma: A Review of Perioperative and Long-Term Outcomes.Diseases (Basel, Switzerland) · 2025Review
- Article
- Review
- Feasibility and safety study of ultra-hypofractionated neoadjuvant radiotherapy to margins-at-risk in retroperitoneal sarcoma.Radiation oncology journal · 2025Article
- Article
- Patterns of care in pancreatic cancer radiotherapy: impact of facility volume on outcomes.Frontiers in oncology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pancreatic cancer is the third leading cause of cancer death in the developed world and is predicted to become the second by 2030. A cure may be achieved only with surgical resection of an early diagnosed disease. Surgery for more advanced disease is challenging and can be contraindicated for many reasons. Neoadjuvant therapy may improve the probability of achieving R0 resection. It consists of systemic treatment followed by radiation therapy applied concurrently or sequentially with cytostatics. A novel approach to irradiation, stereotactic body radiotherapy (SBRT), has the potential to improve treatment results. SBRT can deliver higher doses of radiation to the tumor in only a few treatment fractions. It has attracted significant interest for pancreatic cancer patients, as it is completed quickly, requires less time away from full-dose chemotherapy, and is well-tolerated than conventional radiotherapy. In this review, we aim to provide the reader with a basic overview of current evidence for SBRT indications in the treatment of pancreatic tumors. In the second part of the review, we focus on practical information with respect to SBRT treatment plan preparation the performance of such therapy. Finally, we discuss future directions related to the use of magnetic resonance linear accelerators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.